GX-03: A First-in-Class
Non-Systemic Upstream Approach for Moderate-to-Severe Eczema Lesions Across Mild-to-Severe Disease Extent.
A New Paradigm for Eczema Treatment
GX-03 is designed to intervene at the earliest molecular events that initiate inflammatory skin disease, before chronic inflammation, itch, and barrier breakdown become self-sustaining.
GX-03 delivers its payload via PermaFusion®, our proprietary drug delivery platform – a petrolatum-based, liquid-in-oil suspension technology that enables water-soluble active ingredients to be stably delivered through skin and other keratinous tissue. Rather than suppressing immune activity after inflammation is established, GX-03 prevents unnecessary immune activation by stabilizing the cutaneous microenvironment and modulating epithelial danger signaling.
The result is localized, non-systemic control that addresses IL-36, IL-4, IL-13, and IL-31 signaling through upstream prevention rather than downstream, systemic suppression.
This upstream approach enables meaningful itch reduction and barrier recovery without systemic exposure, injections, or the systemic cytokine blockade that current therapies require
Clinical Development
• Adaptive Phase 2 program underway
• Target population: moderate to severe eczema
• Designed for meaningful efficacy without systemic immune effects
• Developed to address the core biology of eczema
Market Opportunity
• The moderate-to-severe eczema market is dominated by systemic therapies
• Most approved topical therapies treat inflammation after it has already progressed, rather than intercepting it upstream
• Safe, effective reductions in inflammation and pruritus would differentiate clearly from marketed products
• Potential to establish a new therapeutic category with broad patient appeal
